Mitogen-activated protein kinase 14–MAP kinase-activated protein kinase 2 interface (p38α–MK2 interface)

The p38α–MK2 interface is a critical regulatory protein-protein interaction (PPI) site between mitogen-activated protein kinase 14 (p38α) and its downstream effector, MAP kinase-activated protein kinase 2 (MK2) (UniProt Q16539, P49137). This interface involves a specific docking groove on the surface of p38α, known as the Common Docking (CD) domain, which recognizes and binds the D-domain motif of MK2 (Gaestel, 2006). This recruitment is a prerequisite for the phosphorylation and activation of MK2 by p38α, a process that is central to the cellular response to inflammatory cytokines and environmental stress. Once activated, the p38α–MK2 signaling axis regulates the biosynthesis of key pro-inflammatory mediators, such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), primarily through the stabilization and translational control of their mRNA (Schindler et al., 2007). Targeting the p38α–MK2 interface represents a novel therapeutic strategy for treating chronic inflammatory diseases like rheumatoid arthritis and psoriasis, as well as certain malignancies. Unlike traditional p38α inhibitors that compete for the ATP-binding site and often cause systemic toxicity, interface inhibitors (such as the tool compound CMPD1) provide substrate-selective inhibition (Davidson et al., 2004). By blocking the docking groove, these molecules prevent the activation of MK2 while leaving other p38α-mediated pathways intact. This approach is hypothesized to improve the safety profile of p38-targeted therapies by reducing the incidence of hepatotoxicity and skin rashes that have historically led to the failure of clinical trials for broad p38 inhibitors.

Other names

p38α docking groovep38α-MAPKAPK2 complexp38α CD-domainp38α D-site recruitment site

Inhibition of the protein-protein interaction (PPI) between p38α and MK2 by binding to the p38α docking groove (CD-domain), which prevents the recruitment and subsequent phosphorylation of MK2, thereby selectively blocking the production of pro-inflammatory cytokines like TNF-α and IL-6.